See more : Imaspro Corporation Berhad (7222.KL) Income Statement Analysis – Financial Results
Complete financial analysis of BioMarin Pharmaceutical Inc. (BMRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioMarin Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Leeuwin Metals Ltd (LM1.AX) Income Statement Analysis – Financial Results
- Group Five Pipe Saudi Ltd. (9523.SR) Income Statement Analysis – Financial Results
- Polaris Inc. (PII) Income Statement Analysis – Financial Results
- TrueCar, Inc. (TRUE) Income Statement Analysis – Financial Results
- Virtual Medical International, Inc. (QEBR) Income Statement Analysis – Financial Results
BioMarin Pharmaceutical Inc. (BMRN)
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.42B | 2.10B | 1.85B | 1.86B | 1.70B | 1.49B | 1.31B | 1.12B | 889.90M | 751.04M | 548.49M | 500.72M | 441.36M | 376.27M | 324.66M | 296.49M | 121.58M | 84.21M | 25.67M | 18.64M | 12.10M | 13.92M | 11.70M | 12.33M | 6.98M | 1.20M |
| Cost of Revenue | 577.07M | 483.67M | 470.52M | 524.27M | 359.47M | 315.26M | 241.79M | 209.62M | 152.01M | 129.76M | 95.74M | 91.83M | 84.02M | 70.29M | 65.91M | 52.51M | 18.36M | 8.74M | 2.63M | 3.95M | 0.00 | 0.00 | 0.00 | -6.61M | -6.09M | -700.00K |
| Gross Profit | 1.84B | 1.61B | 1.38B | 1.34B | 1.34B | 1.18B | 1.07B | 907.23M | 737.89M | 621.28M | 452.74M | 408.89M | 357.34M | 305.98M | 258.75M | 243.98M | 103.22M | 75.47M | 23.04M | 14.69M | 12.10M | 13.92M | 11.70M | 18.94M | 13.07M | 1.90M |
| Gross Profit Ratio | 76.15% | 76.92% | 74.52% | 71.82% | 78.91% | 78.86% | 81.59% | 81.23% | 82.92% | 82.72% | 82.54% | 81.66% | 80.96% | 81.32% | 79.70% | 82.29% | 84.90% | 89.62% | 89.76% | 78.79% | 100.00% | 100.00% | 100.00% | 153.66% | 187.36% | 158.33% |
| Research & Development | 746.77M | 649.61M | 628.79M | 628.12M | 715.01M | 696.33M | 610.75M | 661.91M | 634.81M | 461.54M | 354.78M | 302.22M | 214.37M | 147.31M | 115.12M | 93.29M | 78.60M | 66.74M | 56.39M | 49.78M | 54.81M | 54.46M | 45.28M | 35.79M | 27.21M | 10.50M |
| General & Administrative | 448.90M | 403.71M | 354.30M | 334.30M | 0.00 | 604.35M | 554.34M | 476.59M | 402.27M | 302.16M | 235.36M | 198.17M | 175.42M | 151.72M | 124.29M | 106.57M | 77.54M | 49.03M | 41.56M | 37.61M | 14.40M | 17.54M | 6.72M | 8.81M | 6.81M | 3.50M |
| Selling & Marketing | 488.40M | 450.30M | 405.10M | 403.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 937.30M | 854.01M | 759.38M | 737.67M | 680.92M | 604.35M | 554.34M | 476.59M | 402.27M | 302.16M | 235.36M | 198.17M | 175.42M | 151.72M | 124.29M | 106.57M | 77.54M | 49.03M | 41.56M | 37.61M | 14.40M | 17.54M | 6.72M | 8.81M | 6.81M | 3.50M |
| Other Expenses | 0.00 | 67.19M | 69.93M | 66.66M | 74.11M | 2.21M | 7.97M | 4.93M | -9.30M | 279.00K | 982.00K | -1.79M | 1.43M | 6.41M | 2.91M | 4.37M | 4.37M | -15.62M | -10.69M | 75.21M | 18.69M | 9.55M | 0.00 | 7.33M | 6.56M | 800.00K |
| Operating Expenses | 1.75B | 1.57B | 1.46B | 1.43B | 1.47B | 1.35B | 1.21B | 1.11B | 1.02B | 781.67M | 608.75M | 519.11M | 389.80M | 299.03M | 242.32M | 204.23M | 160.51M | 100.14M | 87.25M | 162.60M | 87.90M | 81.54M | 52.00M | 51.94M | 40.57M | 14.80M |
| Cost & Expenses | 2.27B | 2.05B | 1.93B | 1.96B | 1.83B | 1.66B | 1.45B | 1.32B | 1.17B | 911.43M | 704.49M | 610.94M | 473.82M | 369.32M | 308.23M | 256.74M | 178.87M | 108.88M | 89.88M | 166.55M | 87.90M | 81.54M | 52.00M | 45.33M | 34.48M | 14.10M |
| Interest Income | 58.34M | 18.03M | 10.48M | 16.61M | 22.75M | 22.83M | 14.85M | 7.49M | 4.50M | 5.94M | 3.08M | 2.58M | 2.93M | 4.11M | 5.09M | 16.39M | 0.00 | 12.87M | 1.86M | 0.00 | 2.56M | 0.00 | 0.00 | 2.98M | 0.00 | 0.00 |
| Interest Expense | 17.34M | 15.97M | 15.34M | 29.31M | 23.46M | 43.66M | 42.71M | 39.50M | 38.24M | 36.64M | 10.45M | 7.64M | 8.35M | 10.33M | 14.09M | 16.39M | 0.00 | 16.73M | 11.92M | 0.00 | 3.13M | 0.00 | 0.00 | 7.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 104.39M | 101.97M | 108.04M | 105.88M | 105.30M | 95.50M | 87.92M | 86.03M | -17.69M | 17.97M | 47.26M | 18.72M | 36.09M | 27.74M | 2.91M | 4.37M | 1.09M | 11.96M | 10.08M | 13.28M | 9.44M | 8.50M | 7.00M | 7.33M | 6.56M | 800.00K |
| EBITDA | 310.28M | 267.52M | 48.03M | -5.85M | 33.95M | -3.54M | 94.76M | -705.53M | -110.70M | -49.96M | -137.36M | -79.84M | -172.00K | 17.07M | 35.63M | 67.45M | -57.29M | -14.88M | -54.47M | -134.63M | -66.36M | -59.12M | -40.63M | -29.94M | -20.38M | -12.10M |
| EBITDA Ratio | 12.83% | 7.61% | 2.60% | -0.31% | -1.31% | -6.72% | -5.46% | -17.23% | -32.28% | -18.34% | -21.66% | -18.36% | -7.24% | 2.15% | 6.72% | 18.28% | -43.52% | -15.10% | -210.91% | -187.38% | -393.95% | -275.52% | -185.07% | -148.73% | -276.20% | -1,058.33% |
| Operating Income | 194.44M | 57.55M | -60.01M | -96.26M | -125.46M | -123.52M | -14.70M | -803.43M | -110.70M | -92.89M | -156.01M | -110.22M | -33.89M | 544.00K | 16.43M | 39.76M | -57.29M | -24.67M | -64.21M | -179.37M | -75.80M | -78.85M | -51.95M | -33.00M | -27.50M | -12.90M |
| Operating Income Ratio | 8.04% | 2.75% | -3.25% | -5.17% | -7.36% | -8.28% | -1.12% | -71.94% | -12.44% | -12.37% | -28.44% | -22.01% | -7.68% | 0.14% | 5.06% | 13.41% | -47.12% | -29.30% | -250.16% | -962.21% | -626.47% | -566.47% | -444.05% | -267.73% | -394.19% | -1,075.00% |
| Total Other Income/Expenses | -5.88M | 14.00K | -15.34M | -5.56M | 5.65M | -19.18M | -35.86M | -27.62M | -44.02M | -31.98M | -20.50M | -8.06M | -9.74M | -22.03M | -15.86M | -6.33M | 42.21M | -3.86M | -10.06M | -8.08M | 5.00K | 1.39M | -18.98M | -7.34M | -3.37M | 600.00K |
| Income Before Tax | 188.56M | 149.58M | -75.35M | -42.32M | -94.81M | -142.71M | -35.88M | -831.05M | -154.72M | -124.87M | -176.50M | -118.28M | -43.63M | -21.49M | 566.00K | 33.42M | -15.07M | -28.53M | -74.27M | -187.44M | -75.80M | -77.46M | -70.93M | -40.34M | -29.17M | -12.30M |
| Income Before Tax Ratio | 7.79% | 7.14% | -4.08% | -2.27% | -5.56% | -9.57% | -2.73% | -74.41% | -17.39% | -16.63% | -32.18% | -23.62% | -9.88% | -5.71% | 0.17% | 11.27% | -12.40% | -33.88% | -289.34% | -1,005.54% | -626.43% | -556.51% | -606.28% | -327.24% | -418.18% | -1,025.00% |
| Income Tax Expense | 20.92M | 8.02M | -11.27M | -901.42M | -70.96M | -65.49M | 81.17M | -200.84M | 17.08M | 9.10M | -150.00K | -3.93M | 10.21M | -227.31M | 1.05M | 2.59M | 729.00K | 23.13M | 21.90M | 36.56M | -5.00K | 9.84M | 19.97M | 4.36M | 573.00K | -600.00K |
| Net Income | 167.65M | 141.56M | -64.08M | 854.03M | -23.85M | -77.21M | -117.04M | -630.21M | -171.80M | -133.97M | -176.35M | -114.35M | -53.84M | 205.82M | -488.00K | 30.83M | -15.80M | -28.53M | -74.27M | -187.44M | -75.80M | -77.46M | -67.61M | -37.36M | -28.07M | -12.30M |
| Net Income Ratio | 6.93% | 6.75% | -3.47% | 45.90% | -1.40% | -5.18% | -8.91% | -56.43% | -19.31% | -17.84% | -32.15% | -22.84% | -12.20% | 54.70% | -0.15% | 10.40% | -13.00% | -33.88% | -289.34% | -1,005.54% | -626.43% | -556.51% | -577.88% | -303.13% | -402.41% | -1,025.00% |
| EPS | 0.89 | 0.76 | -0.35 | 4.75 | -0.13 | -0.44 | -0.67 | -3.80 | -1.07 | -0.92 | -1.28 | -0.95 | -0.48 | 1.99 | 0.00 | 0.31 | -0.16 | -0.34 | -1.08 | -2.91 | -1.22 | -1.45 | -1.65 | -1.04 | -0.94 | -0.55 |
| EPS Diluted | 0.87 | 0.75 | -0.35 | 4.53 | -0.13 | -0.44 | -0.67 | -3.79 | -1.07 | -0.92 | -1.28 | -0.95 | -0.48 | 1.73 | 0.00 | 0.29 | -0.16 | -0.34 | -1.08 | -2.91 | -1.22 | -1.45 | -1.65 | -1.04 | -0.94 | -0.55 |
| Weighted Avg Shares Out | 187.83M | 185.27M | 182.85M | 180.80M | 179.04M | 177.06M | 174.43M | 165.99M | 160.03M | 145.62M | 137.76M | 120.27M | 112.12M | 103.09M | 100.27M | 98.98M | 95.88M | 84.58M | 68.83M | 64.35M | 62.13M | 53.28M | 41.08M | 35.86M | 29.94M | 22.49M |
| Weighted Avg Shares Out (Dil) | 191.60M | 188.96M | 182.85M | 191.68M | 179.04M | 177.27M | 174.43M | 166.22M | 160.03M | 146.35M | 137.76M | 120.27M | 112.12M | 125.67M | 100.27M | 103.57M | 95.88M | 84.58M | 68.83M | 64.35M | 62.13M | 53.28M | 41.08M | 35.86M | 29.94M | 22.49M |
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
Miracle growth: Discover the biotech stock behind decades of jaw-dropping returns
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Source: https://incomestatements.info
Category: Stock Reports